Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q1 EPS of ($1.26), $0.14 worse than the analyst estimate of ($1.12).

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.